Pfizer Inc has requested that the US Food and Drug Administration (FDA) approve a medication that could be used for a cancer treatment to support TGF-beta protein levels in the blood.
TGF-beta is a protein which helps create new blood vessels, and a study published in 2015 found it was responsible for cancer treatment success after the scientists showed that patients who did not have enough TGF-beta production in their bodies performed less well with cancer treatments.
Pfizer is submitting for FDA approval of a drug called CTL019, an injectable antibody drug which targets the TGF-beta gene.
“As a leading global biopharmaceutical company, we are committed to bringing important new therapies to cancer patients who have limited treatment options and derive significant benefit from increased protein availability,” said Jeff Kindler, the president and chief executive officer of Pfizer Inc.
While the data may show a cancer victory over an active tumor, there are some critics who say CTL019 “can probably only achieve minimal clinical benefit,” according to the Boston Globe. “Oncologists such as James Casciato of Weill Cornell Medicine say he fears a further decline in the efficacy of brain-cancer treatments.”